EUVIMEDEUVIMED entdecken
EditorialKommentarLeitlinie

Coronary artery calcium score in the young: is it time to update the guidelines?

Pierre Sabouret iD, Raul D Santos iD

European Journal of Preventive Cardiology · 2024

DOI: 10.1093/eurjpc/zwae050 ↗

Kurz gefasst

Editorial in der Zeitschrift European Journal of Preventive Cardiology, 2024. Verfasst von Pierre Sabouret und 1 weiteren Autor:innen. Beteiligte Einrichtung: Heart Institute and Action Group, Pitié-Salpétrière, Sorbonne University, 47-83 Bd. de l'Hôpital, 75013 Paris, France. Hauptthemen laut MEDLINE: Coronary Artery Disease, Practice Guidelines as Topic, Vascular Calcification. Die Arbeit nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This editorial refers to ‘Coronary artery calcium and the risk of a cardiovascular events and mortality in younger adults: a meta-analysis’, by A. Haq et al. https://doi.org/10.1093/eurjpc/zwad399. Atherosclerotic cardiovascular disease (ASCVD) usually manifests itself after the age of 55 years in men and 65 years in women, disease occurring before these ages is considered as early disease.1 Early ASCVD is associated with either genetic predisposition or the presence of extreme risk factors like familial hypercholesterolaemia, heavy smoking, early onset of hypertension, kidney disease, Type 2 diabetes, substance abuse, or inflammatory conditions.2,3 However, many individuals will manifest early ASCVD without the classical risk factors or non-extreme levels of the latter. The optimal cardiovascular risk assessment remains debated in primary prevention,4 especially for young people. Since in most circumstances, clinical events are preceded by the presence of subclinical atherosclerosis, detection of the latter could be a strategy for risk evaluation in the young.2 In 2019, the ACC/AHA guidelines on primary prevention recommended the use of coronary artery calcium (CAC) score, a robust biomarker of plaque presence and burden,5 as a tool to refine the risk stratification of ASCVD events in people considered at intermediate risk.1 The last ESC guidelines recommend using the updated tool SCORE2 to define individual risk, whereas the use of CAC is currently indicated as Class IIB in middle-aged individuals with ‘apparently moderate’ cardiovascular risk.6 However, how this apply for younger people? Therefore, the results of the meta-analysis of by Haq et al.7 in the European Journal of Preventive Cardiology are of great interest, as the authors report that CAC scores also predict cardiovascular events in a younger population. For that, a study-level meta-analysis comprising 6 studies with 45 919 asymptomatic individuals younger than 55 years (mean age 43.1 years), 69.7% males, without previous manifestations of ASCVD, and who had undergone CAC scoring was performed. The mean follow-up was 12.1 years and of importance 49.1% had a family history of coronary artery disease, 40.4% had hyperlipidaemia, 21.7% hypertension, and 13% smoked. The main study endpoint was a composite of myocardial infarction, ischaemic stroke, and cardiovascular death (major atherosclerotic cardiovascular events-MACE), but the authors also evaluated all-cause mortality and a combination of both endpoints (overall endpoint). As usually done,8 studies were categorized using CAC score cut-offs of 0, 1–100, and > 100 Agatston units. Overall, the presence of any CAC (scores > 0) was associated with an 80% higher risk of adverse events [hazard ratio (HR) 1.80 95% confidence interval (CI) 1.26–2.56, P = 0.012 with a heterogeneity of 65%]. For studies where MACE were tested as endpoints (n = 19 907, mean follow-up 10.9 years, and event rates 1.5–3.8/1000 persons-year), a CAC score 1–100, usually found more frequently in young people when compared with CAC > 100, was associated with an HR of 1.85, 95% CI 1.08–3.16, P = 0.00248, heterogeneity =50.3%. As expected from previous studies, a CAC > 100 showed very high HR for MACE, i.e. 6.57, 95% CI 3.23–13.36, P 100 did (HR = 2.91, 95% CI 2.23–3.80, P 100) was related with both higher risk of MACE and total mortality. The results of Haq et al.7 are robust and clinically relevant; however, the study has several limitations. First, the lack of patient-level data, second, the mix of prospective and retrospective follow-up, third, some endpoints were not common to the six studies and there was variability of MACE and all-cause mortality events among included studies, fourth, the relative short follow-up for a young cohort, and, finally the impossibility to do sub-analyses by age strata and sex. Study strengths include a good characterization of ASCVD risk factors, the use of a reliable and reproducible biomarker such as CAC, and inclusion of representative cohorts from the literature. The findings of Haq et al.7 advocate for the use of cardiovascular imaging to better assess the individual risk due to high heterogeneity of atherosclerosis among young individuals not only classified by the traditional (pool risk equations)1 but also by the new scores (SCORE2).6 Indeed, recent data underline that the cardiovascular risk is not accurately assessed in young people with premature coronary disease as well as in those with chronic inflammation, supporting the need for a specific cardiovascular risk model for this category of patients combining inflammatory biomarkers, microbiota, cardiovascular imaging, proteomics, lipidomics, and polygenic risk scores.2,9 Nevertheless, even if cardiovascular imaging provides a support to doctors in risk assessment in this younger population, some points deserve further comments. First, the current approach of the CAC score should be improved, as the score by itself may not fully reflect the individuals’ risk in young people. Coronary artery calcium should better define risk when it considers the location of calcifications (more risk when the left main or left artery descending are involved), the calcium density and area, the presence of extra coronary calcifications, and the sex differences.10–12 Second, despite the CAC score is associated with risk even in this young population as shown by Haq et al.7 many questions remain unresolved (Figure 1): (A) What are the LDL cholesterol goals according to the CAC score value as no randomized controlled trials (RCT) have been performed in this field especially in the young? One could do an analogy between a CAC score >100 in older people and a MACE risk of at least 0.75% per year as an indication for statin therapy1 or for CAC >100013 with annualized rates of at least 3% as clinical ASCVD risk equivalent patients? Should we reduce LDL-C with pharmacological therapy in individuals with CAC scores 0–100, that are usually more frequent than values > 100 in younger people? Dedicated RCT are warranted to clearly define therapeutic strategies; (B) Should we use aspirin or other antiplatelet agents in primary prevention in the young? Indeed, despite recent guidelines considering aspirin for a CAC > 1001, there is no randomized clinical trial which currently confirms this strategy and other trials using aspirin in primary prevention reported a negative risk–benefits balance;14 (C) Considering the favourable results of CAC absence in older people, the so-called power of zero5, but at the same time the higher risk of non-calcified plaque presence in young populations with risk factors,8 what would be the warranty time for CAC retesting in these individuals? Calcium artery coronary score evaluation in young individuals and its implications for atherosclerotic cardiovascular disease. In conclusion, the CAC score is an unexpensive, non-invasive, and rapid test which allows to better define the ASCVD risk in primary prevention, not only in the middle-aged population with ‘apparent’ moderate cardiovascular risk according to clinical scores,5 but also provides a more accurate evaluation in the young as shown by Haq et al.7 as well as in other specific populations such as individuals with chronic inflammatory diseases or with elevated LDL-C.5,15–17 The cumulative data underlying the usefulness of CAC score advocate an update of the guidelines to better detect and adequately manage more individuals for whom current cardiovascular disease risk scores are suboptimal by missing high-risk patients as well as not starting inadequately lipid-lowering treatment in individuals without subclinical atherosclerosis who only deserve to be followed without medication use and in whom CAC should be repeated.2 The authors would like to recognize the support of Marco Bernardi with figure design. P.S. wrote the first draft, both authors contributed to the development of this manuscript. No external funding was used in the preparation of this article. Not applicable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery DiseasePractice Guidelines as TopicVascular CalcificationHumansCoronary AngiographyPredictive Value of TestsCoronary VesselsAge FactorsAdultRisk AssessmentComputed Tomography Angiography

Autor:innen und Institutionen

  • Heart Institute and Action Group, Pitié-Salpétrière, Sorbonne University, 47-83 Bd. de l'Hôpital, 75013 Paris, France.
  • National College of French Cardiologists, 13 rue Niepce, 75014, Paris, France.
  • Lipid Clinic Heart Institute (InCor), University of Sao Paulo Medical School Hospital, Av. Dr. Eneas C. Aguiar 44, 05403-000, Sao Paulo, Brazil.
  • Academic Research Organization, Hospital Israelita Albert Einstein, Av. Albert Einstein, 627/701, 05652-900, Sao Paulo, Brazil.

ORCID-Profile: Pierre Sabouret, Raul D Santos

Zitieren

APA

Sabouret, P., & Santos, R. D. (2024). Coronary artery calcium score in the young: is it time to update the guidelines?. European Journal of Preventive Cardiology. https://doi.org/10.1093/eurjpc/zwae050

Vancouver

Sabouret P, Santos RD. Coronary artery calcium score in the young: is it time to update the guidelines?. European Journal of Preventive Cardiology. 2024. doi:10.1093/eurjpc/zwae050

BibTeX
@article{Sabouret2024,
  author = {Sabouret, Pierre and Santos, Raul D},
  title = {Coronary artery calcium score in the young: is it time to update the guidelines?},
  journal = {European Journal of Preventive Cardiology},
  year = {2024},
  doi = {10.1093/eurjpc/zwae050}
}
Kostenlos starten →